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Abstract
Tuberculosis is considered to be one of the world’s deadliest disease with 2 million deaths each year. The need for new
antitubercular drugs is further exacerbated by the emergence of drug-resistance strains. Despite multiple recent efforts, the
majority of the hits discovered by traditional target-based screening showed low efficiency in vivo. Therefore, there is
heightened demand for whole-cell based approaches directly using host-pathogen systems. The phenotypic host-pathogen
assay described here is based on the monitoring of GFP-expressing Mycobacterium marinum during infection of the amoeba
Acanthamoeba castellanii. The assay showed straight-forward medium-throughput scalability, robustness and ease of
manipulation, demonstrating its qualities as an efficient compound screening system. Validation with a series of known
antitubercular compounds highlighted the advantages of the assay in comparison to previously published macrophage-
Mycobacterium tuberculosis-based screening systems. Combination with secondary growth assays based on either GFP-
expressing D. discoideum or M. marinum allowed us to further fine-tune compound characterization by distinguishing and
quantifying growth inhibition, cytotoxic properties and antibiotic activities of the compounds. The simple and relatively low
cost system described here is most suitable to detect anti-infective compounds, whether they present antibiotic activities or
not, in which case they might exert anti-virulence or host defense boosting activities, both of which are largely overlooked
by classical screening approaches.
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Introduction
Tuberculosis, a Serious Health Threat
The negative impact that tuberculosis (TB) has on human
health is hard to overestimate. Over one third of the world
population is infected by bacteria of the Mycobacterium tuberculosis
(Mtb) complex. Each year two million TB-related deaths are
registered with 8 million newly infected people [1]. Despite the
efforts of modern therapeutics, in nine of ten cases, Mtb manages
to persist throughout the lifetime causing the risk of reinfection and
reescalation of the disease [2].
The hallmark of TB is the formation of granuloma, well-
organized multicellular structures primarily composed of mature
macrophages and T-lymphocytes. Macrophages often develop into
multinucleated giant cells and epitheloid cells. Granulomas also
contain dendritic cells, neutrophils, NK-cells, fibroblasts and B-
lymphocytes and are surrounded by a fibrous cuff. In addition,
epithelial cells surrounding granulomas are proposed to participate
in its formation. It is generally assumed that the granuloma is a
host-defensive structure that sequesters and eradicates pathogenic
bacteria. Although there is evidence of healed and often sterile
granuloma among certain TB patients, recent findings indicated
that Mtb employs a distinct mechanism of proliferation via
granulomas [22]. Mtb mostly replicates in alveolar macrophages
but can also be found in dendritic cells, adipocytes and type II
alveolar pneumocytes [3–6].
Pathogenic mycobacteria, such as Mtb and other mycobacteria
of the tuberculosis complex, but also Mycobacterium leprae, Mycobac-
terium marinum and Mycobacterium avium are able to manipulate a
variety of processes including membrane trafficking [3,7],
autophagy [8,9], signaling [10] and apoptosis [11,12]. These
manipulations of its host allow the bacteria to hijack the
phagosome and prevent major steps of its maturation by
performing rapid exclusion of the vacuolar H-ATPases [13],
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inhibiting the action of signalling lipids [14,15] and proteins
[16,17] involved in phagosome maturation.
In order to find a way to counteract TB infection, considerable
research efforts focus on a mechanistic study of mycobacterial
virulence factors. One of them is encoded by the RD1 locus, which
was first discovered by investigating the genome deletions in the
attenuated Mycobacterium bovis BCG vaccine strain. Studies
performed also with M. marinum found it to be the main virulence
determinant [18,19]. The locus encodes a type 7 secretion system,
called ESX-1 system [18]. It was shown that RD1 mutants are less
effective in arresting phagosome maturation and are attenuated in
infection dissemination [18,20–23].
TB Treatment, Search for New Drugs
The standard treatment for tuberculosis uses a combination of
antitubercular compounds for six months or longer. The necessity
of extensive treatment was elaborated after a long period of trial
and error. It is now clear that noncompliance with the treatment,
short-term and relaxed therapy regimens result in the emergence
of drug resistant strains. The situation has escalated even further
due to emergence of multi-drug resistant (MDR) strains and,
finally, extensively drug resistant (XDR) strains, and more recently
some totally drug resistant strains have been described [24]. As a
consequence, the WHO reviewed the strategy to fight TB
infections, leading to the establishment of ‘‘directly observed
treatment short course’’ (DOTS) (WHO report 2011).
The newest drug for TB treatment is 30 years old, and the
previously very effective streptomycin lost its efficiency against M.
tuberculosis and is no longer used for therapy. Therefore, the need
for new drugs has become obvious. Several reasons underlie the
lack of new drugs, such as the difficulty to identify compounds that
penetrate mycobacteria, because of the low permeability of the
mycolate-rich cell wall or because of the low metabolic and growth
rates reflected by their 24–36 hours doubling time. In addition,
conventional screening approaches usually favour the search for
bactericidal compounds while at the same time neglecting host-
pathogen interactions.
Despite the challenges mentioned above, several drug candi-
dates are currently under development and have a good chance to
enter the market. Promising approaches for drug development
include targeting synthesis of lipids as nutrients [25,26] and
synthesis of mycolic acids as major components of the cell wall
[27]. In the last decade, researchers have identified compounds
that kill dormant bacteria by intracellular NO release, such as the
bicyclic nitroimidazoles, PA-824 [28], and OPC-67683, as well as
compounds that affect ATP-synthesis such as TMC207 [29] and
nitrofuranylamide compounds with so far unknown mode of
action [30]. Some screens revealed prodrugs that are activated by
the metabolism of the host cell, such as nitroimidazopyran [31].
Potentially interesting compounds also include heterocyclic
aldehydes [32], oxazole- and oxazoline-containing compounds
that target iron uptake [33], and rhodanine derivatives that target
the dihydrolipoamide acyltransferase [34].
Whole-cell Based Screening, a Promising Alternative to
Target-based Approaches
Standard target-based approaches identified compounds that
showed very high attrition rates and low numbers of validated hits
against the intact live bacterium and in infection systems [35,36].
Meanwhile, a broad spectrum of new tools has become available
[37]. A new trend has emerged: phenotypic screens in a whole-cell
infection system [38,39]. Whole-cell screens are a promising
method to provide lead-structures and identify new targets. Unlike
target-based approaches they fulfill in vivo criteria such as
membrane permeability and a higher activity against mycobacte-
ria than host cells. However, whole-cell based assays typically do
not easily reveal the mechanism of action. Additional mechanistic
studies and rounds of structure-activity relationship investigations
are required.
Establishing alternative methods to target-based screening may
improve the chances to discover new sets of drugs that could be
competitive with current drugs, shorten the duration of treatment,
avoid significant drug-drug interactions, and successfully deal with
MDR and XDR Mtb strains. The ability of whole-cell screens to
detect host response in situ makes it possible to reveal not only
antibiotic activities, but also anti-infective drugs. Such compounds
target infection-specific biological processes, and therefore, signif-
icantly reduce the risk of acquiring resistance. A proof of feasibility
for the identification of such active compounds was established in a
few recent studies (reviewed in [40]). For M. tuberculosis, the list
contains inhibitors of iron metabolism [41] and compounds
targeting resistance to oxidative stress [34]. Moreover, whole cell-
based approaches allow detection of compounds that increase the
activity of natural, host-specific innate immune defense mecha-
nisms. This opens the possibility of discovering compounds
capable of helping the host cell deal with a broad range of
pathogens. For example, the cellular pool of kinases and
phosphatases was shown to be the targets of defense-boosting
compounds [39,42–44].
Mycobacterium marinum as a Pathogen Model for Drug
Screening Purposes
As mentioned above, despite the fact that many screens resulted
in the discovery of promising antimycobacterial compounds,
overall screening for anti-Mtb drugs remains ineffective [29,30],
raising the demand for new strategies, including the use of new
and more cost-efficient host-pathogen models.
M. marinum, the closest relative of Mtb in the tuberculosis
complex, is an attractive alternative model. M. marinum is a fish
and frog pathogen which establishes an infection similar to human
tuberculosis [34]. Bacterial growth temperature is optimal at 30uC,
rendering it less dangerous for humans, as it is only capable to
establish superficial skin lesions [45]. Moreover its doubling time
of eight hours is much shorter than that of Mtb and M. bovis BCG,
which in turn improves the speed of detection of antimycobacterial
effects. For M. marinum the mechanisms of phagosome maturation
arrest, as well as the activity of many virulence genes are very
similar to M. tuberculosis [20,46]. M. marinum readily escapes its
vacuole [47], but the efficiency and relevance of this process for
Mtb is still debated [48]. The high degree of functional
conservation in virulence genes supports the theory that ancient
mycobacterial precursors developed the mechanisms of pathogen-
esis against phagocytic protozoa and that mycobacteria are now
using them to hijack animal immune phagocytes [49]. Indeed it
has been shown that free-living amoebae can be an environmental
reservoir for pathogenic bacteria such as M. avium, M. marinum and
even Mtb [50].
For M. marinum, well-developed genetic and cellular biology
tools are available. These features render M. marinum extremely
useful for the investigation of the mode of action of antitubercular
compounds and for the validation with the M. tuberculosis model
[51].
Amoebae Host Systems for Drug Screening
Among whole-cell based assays the usage of unicellular hosts is
advantageous because of the ease of cultivation and manipulation
important in high-throughput screening. Although protozoa do
not engage in complex multicellular interactions, the high degree
Phenotypic Screen for Anti-Mycobacterial Compounds
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of conservation of innate immune defense mechanisms renders
them attractive alternative systems for experimental infection
studies. Within the host one can target multiple pathways involved
at different stages of the infection, including endosomal trafficking
during phagocytosis of the bacteria, the autophagy pathway in the
form of xenophagy, ion-pumps recruitment involved in bacteria
degradation during phagosome maturation, kinases and phospha-
tases signaling that affect the course of infection (reviewed in
[49,52], [53]).
Since the primary target of Mtb is macrophages, amoebae that
are also professional phagocytes, are a rational choice to study
host-pathogen interactions. Amoebae offer a well-balanced com-
promise between the natural complexity of the system on one side
and ease of manipulation and cultivation on the other. Amoebae
and macrophages possess a high degree of functional conservation
in defense mechanisms against infection [54]. Many species of
amoebae serve as a natural reservoir and a training field for
pathogens.
Acanthamoeba are a particularly promising genus of amoebae for
screening purposes. Its environmental niches include soil, air and
fresh water. Unlike Dictyostelium discoideum, a soil-inhabiting social
amoeba that is another popular protozoan model, Acanthamoeba
does not undergo a multicellular developmental phase, which
probably renders them less sensitive to the stress factors inevitable
in screening processes. Acanthamoeba is considered to be a natural
carrier for many mycobacteria species [55], for example it was
shown that 25 mycobacteria species, including non-tuberculous
mycobacteria, can infect both trophozoites and cysts of Acantha-
moeba polyphaga [56–58]. Moreover, intracellular M. avium within
Acanthamoeba castellanii showed increased resistance to bactericidal
compounds such as rifabutin, compared to growth within
macrophages [56,59]. The ability to protect from antitubercular
drugs may serve as an additional in vivo filter to subtract false-
positive hits of drug screening. On the other hand, the D. discoideum
model system has its own unique advantages, particularly a
complete set of genetic tools that are extremely useful for the
determination of mechanisms of action. Together with a fully
sequenced and annotated haploid genome, D. discoideum is
amenable to forward and reverse genetics. Its simplicity of
cultivation makes it easily biochemically tractable. D. discoideum
also allows excellent real-time live imaging. Taken together, both
amoeba genera are useful models, each having its advantages
depending on the purpose of the experiments.
In the present study we have established the A. castellanii – M.
marinum host-pathogen system as a robust compound screening
and validation system. Together with secondary assays using D.
discoideum and M. marinum, it shows excellent promise to identify
novel antitubercular hits.
Results
A Fluorescence- and Cell-based Assay to Measure
Intracellular Mycobacterial Growth in A. castellanii
In this study, we present a fast and easy approach to identify
compounds with anti-infective properties in a cellular host context.
M. marinum is able to replicate efficiently in the free-living fresh
water amoeba A. castellanii [60]. We therefore used A. castellanii to
monitor intracellular growth of M. marinum using a fluorescence-
based assay. A. castellanii was chosen instead of our D. discoideum
model due to its ‘macrophage-like’ size that allows a higher level of
bacteria uptake, easily detectable with our fluorescence plate
reader. The protocol established uses an optimized multiplicity of
infection (MOI) and is based on synchronous and homogeneous
bacterial phagocytosis. Spinoculation of mycobacteria on top of a
cell monolayer close to confluency maximizes host-bacteria
contact and subsequent uptake and thus guarantees high
reproducibility of the infection course. The percentage of infected
cells at time zero and the average number of bacteria per cell is a
function of the MOI (Figure 1A). Using an MOI of 10:1 ensures
that a majority of cells (< 80%) are infected (Figure 1B) with
approximately 1 to 5 bacteria per cell, and thus, this condition
became our infection standard. Then, excess extracellular bacteria
were carefully removed by washing with PYG medium, prior to
testing compounds of interest on infected cells. [61–63]Finally,
infected cells were resuspended in PYG medium containing
amikacin to prevent extracellular growth of bacteria [64]. Using
10 mM amikacin prevented bacteria proliferation in PYG medium
for at least three days (Figure 1C).
In order to adapt the monitoring of infection to a larger scale, a
fluorescence plate reader assay was optimized for the 96-well plate
format. Use of mycobacteria strains expressing fluorescent
reporters has recently been validated for the quantitative
measurement of bacterial mass, as an alternative to c.f.u. counting,
both for microscopy on live and fixed cells and organisms, as well
as higher throughput methods such as microwell-plate readers
[61–63]. The fluorescent M. marinum msp12::GFP strain [65] gave
us the most robust readout to quantitate the increase in bacterial
numbers, but other fluorescent and bioluminescent reporters can
also be used [66]. As shown in figure 1D, the plating density of
initially infected cells (obtained with an MOI 10:1) was a
parameter that greatly impacted intracellular bacterial growth.
As indicated at the right of the graph, the fluorescence fold
increase at 3 days post infection (DPI) was low at high cell density
(1.2 and 1.6 for 2*105 and 1*105 cells/well, respectively) and
bacterial growth kinetics reached a plateau after 30–40 hours post
infection (HPI). In contrast, lower densities that allowed host cells
to grow for at least two days before reaching confluency, resulted
in a higher bacterial expansion (4–6 fold increase with 2 to 5*104
cells/well). Therefore, we decided to plate between 1 and 5*104
infected cells in each well of the 96-well plate.
We validated our assay by monitoring A. castellanii infection
with the non-pathogenic mycobacterium, Mycobacterium smegmatis,
and an avirulent mutant, M. marinum-L1D [65]. As presented in
figure 1E, the total fluorescence of GFP-M. smegmatis decreased
over time, indicating that the bacteria are killed and digested by
the amoebae. In addition, similarly to its fate in zebrafish and
macrophages, the M. marinum-L1D mutant was not able to
replicate in A. castellanii. Similar results have been reported using
the D. discoideum host [47]. However, M. marinum-L1D’s
fluorescence remained stable, indicating that A. castellanii appears
unable to fully digest this strongly attenuated M. marinum strain.
Under our conditions, A. castellanii infection with M. marinum
appeared to severely decrease the growth and/or survival of the
amoebae. Inspection of the wells by phase contrast microscopy
showed that infected A. castellanii cells did not reach maximal
confluency at 3 DPI, concomitantly with a notable accumula-
tion of extracellular bacteria at the well centre (Figure 1F,
arrow). Further inspections showed that heavily infected and
dead amoebae, as well as abnormal giant cells are often
observed during the late phase of infection (Figure 1G,
arrowhead and arrow, respectively). Lethality induced by M.
marinum infection has been reported in many animal systems
such as the Drosophila larvae [67], leopard frog [68], and in
macrophages [69]. Amoeba lysis has also been mentioned as a
result of infection with other intracellular pathogens, such as
Legionella pneumophila [70].
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Figure 1. Mycobacteria infection of A. castellanii. A. Confocal (top) and brightfield (bottom) pictures of A. castellanii infected with GFP-
expressing M. marinum at different MOI. Scale bar, 10 mm. B. Corresponding percentage of infected cells under the three MOI conditions, error bars
represent the standard deviation from technical replicates (three microscopy fields and at least forty counted cells) of one representative experiment.
C. Growth kinetics of M. marinum msp12::GFP in PYG medium supplemented with 10 mM amikacin, representative experiment from a series with
Phenotypic Screen for Anti-Mycobacterial Compounds
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Drug Validation
As a close cousin ofM. tuberculosis,M. marinum is sensitive to most
standard antibiotics used to treat tuberculosis, and also used to
validate various screenings protocols [62,71]. In our host-pathogen
infection model, most first line anti-tubercular drugs are efficient.
Isoniazid (INH), ethionamide and ethambutol were active at
30 mM and efficiently blocked intracellular mycobacterial growth,
only pyrazinamide was not active (Figure 2A). A rifamycin family
derivate, rifabutin, was the most potent antibiotic in our infection
assay with an MIC around 0.25 mM (Figure 2B). We also
confirmed that rifabutin curing of an M. marinum infection
occurred in a dose-dependent manner, and was consistent with
confocal microscopy observations of infected cells (Figure 2B and
C). At three days post infection, the intracellular bacteria load
drastically diminished in presence of rifabutin, as reported by the
total fluorescence intensity of bacteria inside infected cells
(Figure 1). It is notable that rifabutin action on infection also
restored host cell growth in a dose-dependent manner, as judged
by the host cell density in Figure 2C. Finally, we assayed a panel of
known specific anti-tubercular compounds and broad-spectrum
antiobics to treat another intracellular pathogen infection, L.
pneumophila, in the A. castellanii host (Figure 3A). Despite the
common ability of these pathogens to avoid phago-lysosomal
fusion, the Legionella-containing vacuole (LCV) differs from the M.
marinum phagosome-derived compartment, and therefore, as
expected, most of the anti-tubercular antibiotics have no effect
on L. pneumophila replication. Only drugs such as floxacins [72] and
rifampin [73], already reported to be active against L. pneumophila,
cure A.castellanii infected cells.
Because amoebae naturally graze on most innoccuous bacteria
but fail to grow on pathogenic bacteria [74], this discriminating
ability can be used in an alternative screening assay to test
compounds’ ability to restore amoeba growth on a mixture of
pathogenic mycobacteria with non-pathogenic Klebsiella pneumoniae
[75]. As shown in figure 3B, even though this assay is conceptually
different from the GFP-based detection assay, it also detects
specific anti-mycobacterial antibiotics. However, broad-spectrum
antibiotics, such as streptomycin or high concentrations of an anti-
tubercular such as isoniazid, eradicate all bacteria and therefore,
do not allow D. discoideum to generate phagocytic plaques.
Assay Suitability for Drug Screening and Data Analysis
Next, we sought to adapt the GFP-based intracellular growth
assay for medium-throughput analysis using 96-well plates. Border
wells are dedicated to controls needed to test bacteria fitness and
amikacin efficiency (Figure 4A). As rifabutin efficiently cures the
infection, we decided to include it in the experimental plate design
as positive control. Wells containing DMSO (at 1%, as compound
carrier) and rifabutin (10 mM) are used as negative and positive
controls, respectively. Therefore, 64 compounds can be tested per
96-well plate. We next measured the quality of our screening
protocol to detect potential hits by calculating a Z factor that is a
usual parameter to assess screen robustness [76]. From a single
standard infection, cells were dispensed in 96-wells, half containing
DMSO and half containing 10 mM rifabutin, as shown in
figure 4B. The assay sensitivity is high as both controls are clearly
separated and, as attested by the standard deviation of the mean,
variability between identical wells is low. In both cases, the end-
point fluorescence values at 3 days post infection (DPI) were
normally distributed. Overall assay robustness is attested by a Z
factor score of 0.74 that is excellent for an ‘in vivo’ biological assay,
and allows to initiate compounds screening with reasonable
confidence.
To allow direct comparison from several plates and multiple
infection rounds, raw fluorescence kinetic data (figure 4C, left
curve) were transformed. First, to integrate the entire history of the
growth kinetics, cumulative curves were built rather than simply
using the endpoint measurements were built, and the first point
was standardized to 0 by subtracting the value at time zero from
each data point (Figure 4C, middle) were transformed as follows.
Second, the last value point was standardized to 1 for the mean
value of the DMSO controls (Figure 4C, right). Next, normalized
cumulative values were ranked relative to the increase or decrease
of bacterial growth compared to the DMSO. Representative
results from a single experimental plate are presented in figure 4D.
The plot represents the difference between the DMSO mean value
and each compound of interest. The significance of a compound’s
effect was first statistically assessed by its difference from the
DMSO control, a difference of more than two or three standard
deviations of the DMSO mean being considered significant.
Moreover, the strength of inhibition or promotion of bacterial
growth was measured by its relative normalized score compared to
1 (DMSO).
Workflow and Secondary Assays
In order to successfully conduct a screen to identify potential
compounds of interest in a complex biological assay, secondary
assays are often established and implemented prior to further
structure activity relationship studies. In our specific assay setting,
two further and major pieces of information can be easily
extracted: compound toxicity to the host alone, and antibiotic
effect on the bacterium in vitro. A basic representation of the screen
workflow is presented in figure 5A. The effect of the hit
compounds on the host growth and health was tested in the plate
reader format with a D. discoideum strain expressing a fluorescent
reporter, GFP-ABD [77]. For example, we monitored the growth
kinetic of this strain in the presence of a classical anti-tubercular
antibiotic, ethambutol, and a toxic compound, nicotin (Figure 5B).
Ethambutol produced no detectable effect on D. discoideum growth,
as also observed with most classical antibiotics tested so far,
whereas nicotin affects cell growth in a dose-dependent manner
(Figure 5B).
A similar assay was used to test the antibiotic activity of the hit
compounds directly on M. marinum in its standard culture broth
(7H9). For example, fusidic acid, a second line antibiotic used for
tuberculosis treatment was tested at various concentrations on
extracellular and intracellular M. marinum, (Figure 5C). In both
cases a half inhibitory concentration (IC50) can be calculated. IC50
values obtained with a small collection of classical anti-tubercular
antibiotics are presented in Table 1. Overall, the data highlight a
similar outcome. D. Growth kinetics of GFP-expressing M. marinum within A. castellanii plated at different densities, measured by total fluorescence
intensity. The standard deviation derives from the technical mean of eight microwells. The values on the right represent the fold fluorescence
increase between 2 and 68 hours post infection. E. Representative experiment of growth kinetics of GFP-expressing M. smegmatis, M. marinum WT
and L1D mutant strains within A. castellanii, measured by fluorescence intensity. F. Brightfield microscopy of the cells at the bottom of a microwell.
Infected cells at 3 DPI under control conditions and non-infected cells. Scale bar is 100 mm. G. Phase contrast (top) and confocal (bottom) pictures of
A. castellanii infected cells with GFP-expressing M. marinum at three days post-infection. Infected giants cells (arrow), and some dead cells
(arrowhead) are observed. Scale bar, 10 mm.
doi:10.1371/journal.pone.0087834.g001
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shielding effect of the amoeba host, protecting the mycobacteria
from the antibiotics, as previously demonstrated using M. avium
[59]. In our assay, only rifabutin showed a better effect when
tested as anti-infective in vivo rather than as antibiotic in vitro. This
phenomenon is probably explained by its higher liposolubility,
which likely enhanced membrane permeability and consequently
increased its concentration inside the host cell [78].
Discussion
In the present study, we detail a screening method to detect
anti-tubercular compounds acting in the context of infected
amoeba host cells. We first developed and validated suitable
conditions for medium throughput screening (MTS). We used
fluorescent mycobacteria to monitor intracellular growth in real
time by recording fluorescence increase in a 96-well microplate
reader. So far, the use of fluorescent mycobacteria is a consensus
to avoid the counting of colony forming units, which is hardly
compatible with MTS procedures, and allow a fast and reliable
way to measure bacterial growth. However, some obvious
limitations are due to this detection method. There is no direct
way to known how healthy the remaining bacteria are, whose
fluorescence remains stable over time. Presently, only a clear
decrease in fluorescence intensity, as observed with rifabutin,
reflects of a probable bactericidal effect. The long half-life of GFP
and the resistance of mycobacteria to cell lysis conferred by their
Figure 2. Effect of antibiotics on intracellular growth of M. marinum during an infection. A. Intracellular growth kinetic of GFP-expressing
M. marinummeasured by fluorescence intensity in the presence of 30 mM of first-line antibiotics. B. Intracellular growth kinetics of GFP-expressing M.
marinum measured by fluorescence intensity, in the presence of different concentrations of rifabutin. A and B are representative experiments from a
series with similar outcome. C. Effect of rifabutin on M. marinum growth during an infection. Brightfield (top) and spinning disc confocal (bottom)
imaging of A. castellanii infected with GFP-expressing M. marinum in the presence of the indicated concentrations of rifabutin, 72 hours post
infection.
doi:10.1371/journal.pone.0087834.g002
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particularly thick cell wall partly explain this phenomenon.
Moreover, with this readout, compounds that interfere with cell
metabolism, expression of the reporter, or quench its fluorescence
can be identified as false positives.
Additionally, introducing host cell-specific fluorescent markers
allows the dissection of compound effects on various cell processes
like phago-lysosomal trafficking, autophagy induction or lipid
storage. Altogether, these fluorescent cell-based approaches can
Figure 3. Effect of antibiotics on intracellular growth of L. pneumophila during an infection and in a ‘phagocytic plaque assay’. A.
Left, representative experiment from a series with similar outcome of intracellular growth kinetic of GFP-expressing L. pneumophila measured by
fluorescence intensity in the presence of 30 mM of antibiotics. Right, normalized intracellular bacterial growth (DMSO=1) in A. castellanii, error bars
represent the standard deviation from biological triplicates. B. Ability of D. discoideum DH1 strain (1000 cells/well) to grow on a bacterial lawn
composed of M. marinum and Klebsiella pneumoniae (2::1 ration) after seven days and in presence of antibiotic compounds.
doi:10.1371/journal.pone.0087834.g003
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Figure 4. Screening protocol for anti-tubercular compounds. A. Scheme of the plate design in 96-well format for compounds screening. B.
Left, representative experiment of intracellular growth kinetic of GFP-expressing M. marinum measured by fluorescence intensity obtained from
one control 96-well plates in presence of DMSO (N=48) or 10 mM of rifabutin (N = 48). The small graphs on the right represent the normal
distribution of the fluorescence difference between 2 and 72 hours of infection for DMSO and rifabutin. Consequently, the Z factor of this experiment
was 0.74. C. For the statistical analysis, the data are treated in three steps. First, from the raw data, the value at 68 hours is subtracted from all others
and a cumulative fluorescence curve is drawn. Then, the curves are normalized to the DMSO standard control. Graphs are representative of one
experimental screening plate. D. Differential fluorescence values obtained from one experimental plate with diverse compounds are plotted.
Horizontal bars represent 3-fold standard deviation from the DMSO mean. The green dot corresponds to the normalized DMSO controls; the orange
dot to a putative pro-infectious compound; the black dot to the average of the rifabutin controls; the two red dots to two putative anti-infective
compounds. The graph is representative of one experimental screening plate.
doi:10.1371/journal.pone.0087834.g004
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easily be adapted to monitor multiples parameters in a high-
content microscopy approach [38]. Therefore, integration of these
secondary readouts can provide preliminary knowledge about the
mode of action of a compound [39].
As expected, the initial conditions of the infection largely
influence the kinetics of bacterial growth. Multiple parameters
(percentage of infected cells, cell density, host and bacteria
physiological state) modulate the final apparent increase over
almost a log range (data not shown). We clearly observe that
exponentially growing host cells facilitate bacterial expansion,
whereas high confluence partially suppresses it. These findings
suggest that cell-to-cell transmission, as observed in D. discoideum, is
also a significant parameter in A. castellanii infections [47].
Surprisingly, depending on the initial bacterial load, the
mycobacteria infection leads to host cell death between two to
five DPI. Significant cytotoxicity towards the host cell has not been
reported during D. discoideum infection [79], but was previously
noted in macrophages infected by M. tuberculosis and M. marinum at
high MOI and under conditions where phagosomal rupture
occurred [69,80]. Modulation of apoptotic and necrotic cell death
has been reported in macrophages infected with virulent and
avirulent strains of M. tuberculosis [81]. However, in the absence of
caspase-dependent apoptotic pathways in amoebae, infection by
M. marinum likely leads to the necrotic and/or autophagic cell
death, mechanistically perhaps similar to the pathways document-
ed in the model amoeba D. discoideum [82].
IC50 determination of antibiotics in extracellular conditions and
within the amoeba host emphasizes the shielding role of A.
castellanii, as previously shown forM. avium [59]. This capacity of A.
castellanii to protect against antibiotics may be due to a lower
Figure 5. Secondary assays for identifying compounds properties. A. Basic scheme of screen workflow including the growth inhibition/
cytotoxicity assay and the antibiotic assay before hit validation in other host models system. B. Growth inhibition/cytotoxicity assay. Growth kinetics
of GFP-expressing D. discoideum AX2 cells measured by fluorescence intensity, in the presence of various concentrations of ethambutol (top) or
nicotin (bottom). C. antibiotic assay. Left, intracellular and Right, intracellular growth kinetic of GFP-expressing M. marinum measured by
fluorescence intensity in the presence of various concentrations of fusidic acid, accompanied by the corresponding graphs for IC50 determination. B
and C are representative experiments from a series with similar outcome.
doi:10.1371/journal.pone.0087834.g005
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membrane permeability and/or enhanced host efflux pump
mechanisms that purge intracellular drugs. This observation
implies that our assay operates at high stringency to select hit
compounds with low IC50. Even if direct comparison of anti-
tubercular intracellular IC50 obtained in various studies is difficult,
because of the differences in conditions used (MOI, time
resolution), bacterial strains (M. tuberculosis, BCG, M. marinum)
and host (macrophages, amoeba, zebrafish, D. melanogaster), the
IC50 we calculate for our assay reveal a similar shielding effect as
seen for other mycobacteria such asM. avium during infection in A.
castellanii [59].
In this study, we reported successful activity of most known anti-
tubercular antibiotics to eradicate or attenuate intracellular M.
marinum growth, with the exception of pyrazinamide. It is known
that a low acidic pH is needed to convert pyrazinamide into an
active drug, pyrazinoic acid [83], and so far, no data has been
published about the pH inside the mycobacteria-containing
compartment in amoebae. As discussed in a study reporting about
the D. melanogaster/M. marinum infection model [84], a lack of
vacuole acidification could lead to a poor conversion of the pro-
drug into its active form, and thus might explain the inefficiency of
pyrazinamide in our system. In addition, a recent paper Ahmad
et al [85] showed that the minimum inhibitory concentration of
pyrazinamide against M tuberculosis and M. bovis is high. Finally,
several Mycobacteria strains such as M. canettii are naturally
resistant to pyrazinamide [86], as well as clinical isolates of M.
kansasii and M. marinum [87]. Therefore, a higher concentration of
pyrazinamide could be needed to impact on M. marinum
replication in our system.
From our standard experimental data, we calculated a Z factor
that lies between 0.6 and 0.8, values that are commonly accepted
as highlighting the robustness of an assay [76]. Moreover, we also
present here the flow of statistical data analysis that guides us to
identify primary hits. Transformations of the raw kinetic data are
made to take into account the global history of the growth curve
and not only the difference between the values at the first and last
time points. This method allows for the robust detection of both
anti-infective and pro-infective molecules. Finally, our workflow
comprises two secondary assays. A growth inhibition assay using
fluorescent D. discoideum is used to determine an IC50 for negative
effects on the host. This allows then to estimate a therapeutic
window between effects on the intracellular bacteria and on its
host. Yet, the data obtained for amoebae have to be validated for
mammalian host cells, e.g. macrophages. The antibiotic assay
performed on extracellular bacteria is used to quantitate the
difference in efficacy between the effect of the compound on
extracellular versus intracellular bacteria, which will permit to
identify compounds with most relevant anti-infective activities,
being anti-virulence or host defence-boosting mode of action.
Overall, we detailed the establishment of an MTS pipeline for
an ‘in vivo’ anti-tubercular screen allowing to test in moderate
turnover time, 64 molecules per 96-well plates, with excellent
sensitivity and good anti-mycobacterial specificity. Finally, we
speculate that the use of amoebae hosts, which are natural vectors
for many bacteria and have already proven powerful in the
elucidation of mechanisms underlying host-pathogen relationships
[47,79], also represent a worthy alternative model to contribute to
hit and lead identification and drug development to fight
tuberculosis.
Materials and Methods
Bacteria and Cell Cultures
Acanthamoeba castellanii (ATCC 30234) was grown in PYG
medium at 25uC as described (Moffat and Tompkins, 1992; Segal
and Shuman, 1999) using proteose peptone (Becton Dickinson
Biosciences) and yeast extract (Difco). The D. discoideum strain
expressing GFP-ABD [71] was grown in HL5c medium at 22uC.
Mycobacteria, the M. marinum M-strain (wild-type), the L1D
mutant [65] and M. smegmatis (generous gift from Gareth Griffiths)
were cultured in Middlebrook 7H9 (Difco) supplemented with
10% OADC (Becton Dickinson), 5% glycerol and 0.2% Tween80
(Sigma Aldrich) at 32uC in shaking culture. M. marinum and the
msp12::GFP plasmid were gifts from Dr. L. Ramakrishnan
(Washington University, Seattle, USA). The M. marinum strain
expressing GFP in a constitutive manner was obtained by
transformation with msp12::GFP, and cultivated in the presence
of 20 mg/ml kanamycin.
Acanthamoeba Infection Assay
A. castellanii were cultured in PYG medium in 10 cm Petri dishes
at 25uC, and passaged the day prior to infection to reach 90%
confluency. M. marinum were cultivated in a shaking culture at
32uC to an OD600 of 0.8–1 in 7H9 medium. Mycobacteria were
centrifuged onto a monolayer of Acanthamoeba cells at an MOI of
10 to promote efficient and synchronous uptake. Centrifugation
was performed at RT at 500 g for two periods of 10 min. After an
additional 20–30 min incubation, extracellular bacteria were
washed off with PYG and infected cells were resuspended in
PYG containing 10 mM amikacin. 56104 infected cells were
transferred to each well of a 96-well plate (Cell Carrier, black,
transparent bottom from Perkin-Elmer) with preplated com-
pounds and controls. The course of infection at 25uC was
monitored by measuring fluorescence in a plate reader (Synergy
H1, BioTek) for 72 hours with time points taken every 3 hours.
Time courses were plotted and data from all time points were used
to determine the effect of compounds versus vehicle controls. To
take into account possible autofluorescence of the compounds,
RFU data of the first time point were subtracted from all time
points. Cumulative curves were calculated. The activities of the
compounds were determined by analysing maximum difference of
compound cumulative curve to the 12–16 vehicle controls.
Table 1. Inhibitory concentrations 50% (IC50) values for M.
marinum growth in extracellular and intracellular conditions.
antibiotic extracellular IC50 (mM) intracellular IC50 (mM)
streptomycin 0.1–1 3–7
fusidic acid 0.01–0.1 3–5
ethionamide 0.1–1 3–10
isoniazid 5–10 20–30
rifampin 0.1–0.5 3–10
rifabutin 2–3 1–3
ethambutol 5–10 5–10
levofloxacin 10–30 .30
moxifloxacin 5–10 .30
thioridazine 1–5 5–10
PA-824 3–5 5–10
As presented in Figure 5C, GFP-expressing M. marinum growth kinetics were
measured in broth culture and during cellular infection in presence of
antibiotics in a concentration range, and IC50 values were graphically
determined from a series of experiments with similar outcome.
doi:10.1371/journal.pone.0087834.t001
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Fluorescence Microscopy
Acanthamoeba cells were infected with GFP-expressingM. marinum
as described above. Infected cells were monitored in 96-well plates
(Cell Carrier, black, transparent bottom from Perkin-Elmer).
Recordings were performed using a Leica LF6000LX microscope
(100x 1.4 NA oil immersion objective).
Phase Contrast Microscopy
Acanthamoeba cells were infected with GFP-expressingM. marinum
as described above. Infected cells were monitored in 96-well plates
(Cell Carrier, black, transparent bottom from Perkin-Elmer).
Recordings were performed using a CKX41 inverted microscope.
Antibiotic Activity Assay
104 GFP-ABD-expressing D. discoideum cells were transferred to
each well of 96-well plates allowed to attach for 20–30 min. Cell
growth at 25uC was monitored by measuring the GFP fluores-
cence in a fluorescent plate reader (Synergy H1, company) for 72
hours with a time point taken every 3 hours.
Growth Inhibition Assay
105 GFP-expressing M. marinum were transferred to each well of
96-well plates. Bacterial growth at 25uC was monitored by
measuring the GFP fluorescence in a fluorescent platereader
(Synergy H1) for 72 hours with a time point taken every 3 hours.
Statistical Analysis
The Z factor was calculated using the means and standard
deviations of both positive and negative controls (mp, sp and mn,
sn). The following formula was applied: Z-factor = 1–3(sp+ sn)/
|mp-mn|.
Intracellular Replication of L. pneumophila
A. castellanii amoebae were cultured in PYG medium and
passaged the day prior to infection such that 26104 cells were
present in each well of a 96-well plate (Cell Carrier, black,
transparent bottom from Perkin-Elmer). Cultures of L. pneumophila
harbouring the GFP-producing plasmid pNT-28 were resus-
pended from plates to a starting OD600 of 0.1 in AYE medium,
and grown overnight on a rotating wheel at 37uC to an OD600 of
3. Bacteria were diluted in LoFlo medium (ForMedium) such that
each well contained 86105 bacteria, an MOI of 20. Infections
were synchronised by centrifugation at 1500 rpm for 10 minutes.
Infected cultures were incubated in a 30uC incubator and the GFP
fluorescence was measured by a plate spectrophotometer at
appropriate intervals (Optima FluoStar, BMG Labtech) [88].
Time courses were constructed and data from the point directly
after entry up to stationary phase were used to determine the effect
of compounds versus vehicle control.
Dictyostelium Growth on a Bacteria Lawn
Because D. discoideum cannot grow on lawns of virulent M.
marinum, a specific growth assay was developed [89]. It consists in
resuspending a pellet from one volume of centrifuged mid-log
phase mycobacterial cultures in an equal volume of an overnight
culture of K. pneumoniae diluted 105 fold. Then, 50 ml aliquots of the
bacterial suspension were plated on 2 mL plugs of solid
SM+Glucose agar medium in a 24-well plate format and left to
dry for 2–3 hours. Finally, 1,000 D. discoideum cells were added on
top of the bacterial lawn. Plates were incubated for 5–9 days at
25uC and the formation of phagocytic plaques was monitored and
quantified.
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